Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics announced positive long-term data from the Phase 1 study of NTLA-2002, a CRISPR-based gene editing therapy for hereditary angioedema (HAE). The data showed that eight out of ten patients remained attack-free following a 16-week primary observation period and continued to show positive results for over two years. A single dose of NTLA-2002 led to a 98% reduction in monthly HAE attacks. All patients who stopped prophylaxis treatment remained free from chronic treatment. The therapy demonstrated a favorable safety profile with mild adverse events. The company plans to begin a Phase 3 trial in the second half of 2024.
Intellia Therapeutics, Inc. announced strong financial results and progress in gene editing therapies for various diseases. They are rapidly enrolling patients in Phase 3 trials for ATTR amyloidosis, planning new Phase 3 trials for other conditions, and presenting clinical data in 2024. The company ended Q1 2024 with approximately $953 million in cash.
Intellia Therapeutics, a gene editing company, will discuss its first quarter 2024 financial results and operational highlights on May 9, 2024. The conference call will focus on revolutionizing medicine with CRISPR-based therapies. Investors can join the call via phone or webcast.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) will present updated data from the Phase 1/2 study of NTLA-2002 for the treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024. The presentation will cover safety, kallikrein reduction, and attack rate data. The company will also host an investor webcast on June 3, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.